scholarly journals Pruritus: Progress toward Pathogenesis and Treatment

2018 ◽  
Vol 2018 ◽  
pp. 1-12 ◽  
Author(s):  
Jing Song ◽  
Dehai Xian ◽  
Lingyu Yang ◽  
Xia Xiong ◽  
Rui Lai ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Signaling Pathways ◽  
Therapeutic Strategies ◽  
Therapeutic Options ◽  
Specific Mechanism ◽  
Cutaneous Symptom

Pruritus, the most common cutaneous symptom, is widely seen in many skin complaints. It is an uncomfortable feeling on the skin and sometimes impairs patients’ quality of life. At present, the specific mechanism of pruritus still remains unclear. Antihistamines, which are usually used to relieve pruritus, ineffectively work in some patients with itching. Recent evidence has suggested that, apart from histamine, many mediators and signaling pathways are involved in the pathogenesis of pruritus. Various therapeutic options for itching correspondingly have been developed. In this review, we summarize the updated pathogenesis and therapeutic strategies for pruritus.

scholarly journals Genital psoriasis: Update on clinical practices and therapeutic options

2021 ◽  
Vol 68 (1) ◽  
pp. 48-51
Author(s):  
Emanuela-Domnica Boieriu ◽  
◽  
Iulia-Elena Negulet ◽  
Ioana-Simona Dinu ◽  
Alexandra-Irina Butacu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Life Quality ◽  
Clinical Findings ◽  
Therapeutic Options ◽  
Topical Steroids ◽  
Clinical Practices ◽  
Clinical Variants ◽  
Genital Psoriasis ◽  
Chronic Skin

Psoriasis is a chronic skin disease with an important inflammatory compound which associates a worldwide prevalence of 0.5% to 8.5%. The involvement of the genital region can be associated with both plaque psoriasis and inverse psoriasis and survey-based studies indicate that up to 45.5% of patients present lesions of genital psoriasis. Genital psoriasis represents a frequent encounter of psoriasis which is often overlooked and which associates a significant impact on their quality of life, measured by Dermatology Life Quality Index (DLQI) scores which are twice as high as those of psoriatic patients without genital involvement. Recognising the specific clinical findings represents an important step in establishing the diagnosis and case management. Classical therapeutic options such as topical steroids or modern treatments such as ixekizumab represent important tools in fighting this affliction and regaining the patient’s quality of life. This review aims to emphasize the up-to-date clinical variants of genital psoriasis, the consequences on the quality of life of patients and to present the newest therapeutic options.

scholarly journals COVID-19 clinical implications: the significance of nanomedicine

Bioimpacts ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. 137-138
Author(s):  
Jaleh Barar
Keyword(s):  
Quality Of Life ◽  
De Novo ◽  
Virus Entry ◽  
Therapeutic Strategies ◽  
Clinical Implications ◽  
Molecular Signaling ◽  
Key Factor ◽  
To Come

COVID-19 pandemic has profoundly affected the lives of humans worldwide. We no longer experience the same quality of life and need to come up with effective solutions to combat the clinical implications. The vast knowledge about the pathways that regulate the virus entry and molecular signaling of the pathogenesis of coronavirus are the key factor for the development of de novo diagnostic/therapeutic strategies. Meanwhile, the emergence of nanotechnology, could offer enormous help in the battle against coronavirus. In this editorial, the role of molecular elements in the pathobiology of the disease and the significance of nanoscaled pharmaceuticals is highlighted.

scholarly journals 592 The growth of telehealth during SARS-CoV-2 time

2021 ◽  
Vol 23 (Supplement_G) ◽  
Author(s):  
Mario Ferraiolo ◽  
Emily Di Trocchio ◽  
Paola Follero
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Emergency Room ◽  
Therapeutic Strategies ◽  
Hospital Environment ◽  
Digital Platform ◽  
Patient Reports ◽  
Remote Transmission ◽  
Approval Rating

Abstract Aims Improve the management of frail patients, particularly in times of pandemic, through an assistance based on a remote digitalized platform, which allows rapid interventions, able to reduce access to the emergency room, and decreased mortality from cardiovascular causes. Methods and results (i) Heart failure management—Enrollment in the digital platform. Use of devices: sphygmomanometer, scale, oximeter, single-track ECG. Daily analysis of the haemodynamic parameters on the platform. Communication by e-mail exchange and tele/videoconsultations, drug management, and therapeutic strategies. Possibility to perform echocardiogram at home. (ii) Remote monitoring management—Enrollment in the digital platform. Supply of transmitters for the management of thresholds, objectives, and alarms. Daily parametric check. (iii) Infarct network management—Integrated operating system for assistance between the in-hospital and out-of-hospital environment, in patients suffering from AMI. Execution, transmission, and reporting of the ecg-graphic trace on equipment provided with a remote transmission system. Allow to reduce the time of diagnosis and treatment. At our centers, over 1000 patients are followed on a digital platform, including those at risk of heart failure and device wearers. In addition, there is an annual trend of over 400 patients who are diagnosed electronically with AMI and relative percutaneous coronary treatment. The use of remote systems has allowed for some patients to early highlight threatening arrhythmias and/or device malfunctions, for others to prematurely intercept symptoms and signs of congestive heart failure. A clear improvement in prognosis and quality of life was therefore observed. Conclusions Cardiovascular diseases are the leading cause of death in Western countries. Therefore, the close follow-up and identification of haemodynamic and clinical parameters on digitized platforms, allows to: reduce access to the emergency room, guarantee the best therapeutic strategies, improve the quality of life, and decrease the mortality rate. In conclusion, we found a high approval rating as the patient reports feeling better, feeling constantly followed, and a clear improvement in compliance and adherence to the therapy.

scholarly journals Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer

2020 ◽  
Vol 130 ◽  
pp. 102-113 ◽  
Author(s):  
Monika Klinkhammer-Schalke ◽  
Brunhilde Steinger ◽  
Michael Koller ◽  
Florian Zeman ◽  
Alois Fürst ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Randomised Trial ◽  
Therapeutic Options

Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomized trial including 220 patients with colorectal cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 10050-10050
Author(s):  
Monika Klinkhammer-Schalke ◽  
Brunhilde Steinger ◽  
Michael Koller ◽  
Alois Fürst ◽  
Pompiliu Piso ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Randomized Trial ◽  
Therapeutic Options

A phase II study to evaluate the safety and efficacy of OQL011 on VEGFR inhibitor-associated hand-foot-skin reaction in cancer patients.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. TPS12132-TPS12132
Author(s):  
Mario E. Lacouture ◽  
Milan J. Anadkat ◽  
Omkar Subhash Marathe ◽  
Nicholas J. Vogelzang ◽  
Elaine Tat Lam ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Signaling Pathways ◽  
Skin Reaction ◽  
Vehicle Control ◽  
Life Questionnaire ◽  
Safety And Efficacy ◽  
Patient Reported ◽  
Hand Foot Skin Reaction ◽  
Dose Levels

TPS12132 Background: Hand-Foot Skin Reaction (HFSR) is frequently associated with the use of multi-targeted tyrosine kinase inhibitors of the vascular endothelial growth factor receptor (VEGFRi) such as cabozantinib, regorafenib, sunitinib, and lenvatinib. HFSR affects the skin on the palms and soles and is manifested as edema, erythema, hyperkeratosis, and bullae, leading to a decrease in quality of life and interruptions in dosing. The incidence of HFSR differs among VEGFRi, ranging from 5-60% (all grades) and 1-18% (grade 3). To date, there is no FDA approved treatment for HFSR, and marginal benefit has been shown with topical urea or steroids. Although not fully elucidated, the pathogenesis of HFSR has been associated with impaired vascular repair mechanisms, caused by inhibition of VEGF signaling pathways. We hypothesize that topical stimulation of VEGFR through OQL011 will decrease the severity of HFSR symptoms via local upregulation of the VEGF/VEGFR related signaling pathways. Methods: NCT04088318 is a phase 2, double-blind, randomized controlled trial to evaluate the safety and efficacy of OQL011 compared to vehicle control in the treatment of moderate to severe HFSR in patients on VEGFRi therapy. Eligible patients will have ≥ grade 2 palmar plantar erythrodysesthesia (PPE). The study is expected to enroll 112 patients in two parts. In the first part, 42 patients will apply 0.2% OQL011 topical ointment or vehicle control (2:1 randomization) TID for six weeks. In Part 2, 70 subjects will be randomized into two additional dose levels or vehicle control in a 2:2:1 ratio. The two dose levels selected will be based on the efficacy and safety results of Part 1. The primary efficacy endpoint is improvement of NCI CTCAE v5.0 PPE to grade ≤1 by week 3. Photographs of the affected areas will be taken at Day 0, 7, 14, 21 and 42 timepoints. Superiority test will be performed to compare treatment groups, and the exposure-response relationship will be explored. In addition, an investigator global assessment (IGA) for HFSR will be used in this trial to specifically assess skin recovery and is proposed to be a new evaluation tool. The validity of IGA criteria will be evaluated by assessing the inter-rater and intra-rater reliability. The correlation between IGA, NCI CTCAE v5.0 for PPE, and patient reported outcomes including Visual Analog Scale of Pain, Hand-foot Quality of Life questionnaire will also be evaluated. This study began enrolling patients in December 2019 and is ongoing. Clinical trial information: NCT04088318.

The European Organisation for Research and Treatment of Cancer Imaging Programme

2010 ◽  
Vol 06 (01) ◽  
pp. 92
Author(s):  
John Bean ◽  
Jocelyne Flament ◽  
Pascal Ruyskart ◽  
Françoise Meunier ◽  
◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trials ◽  
Clinical Research ◽  
Cancer Treatment ◽  
Cancer Imaging ◽  
Therapeutic Strategies ◽  
Cancer Clinical Trials ◽  
Imaging Technologies ◽  
European Organisation

The European Organisation for Research and Treatment of Cancer (EORTC), an international organisation under Belgian law, develops, conducts, co-ordinates and stimulates translational and clinical research in Europe aimed at improving the management of cancer and related problems by increasing survival and also improving patient quality of life. Imaging is now playing an increasingly important role in the treatment of cancer, and in order to further its mission to improve the standard of cancer treatment through the testing of more effective therapeutic strategies, the EORTC has initiated a cancer imaging programme. The objectives of this programme are to build an image exchange platform for cancer clinical trials, create an EORTC Imaging Group, network with stakeholders in cancer imaging, stimulate the integration of imaging components into EORTC studies, participate in major EU initiatives and link up with US co-operative groups. The EORTC is dedicated to improving the quality and consistency of evaluation of cancer treatment within its clinical trials through the incorporation of imaging technologies used for treatment definition for radiotherapy, staging, prediction and evaluation of response, or pathology.

scholarly journals Anxiety: a hidden element in dementia

2012 ◽  
Vol 18 (2) ◽  
pp. 119-128 ◽  
Author(s):  
Vellingiri Raja Badrakalimuthu ◽  
Andrew F. Tarbuck
Keyword(s):  
Quality Of Life ◽  
Cognitive Impairment ◽  
Anxiety Disorders ◽  
Old Age ◽  
Negative Impact ◽  
Poor Quality ◽  
Therapeutic Options ◽  
Prevalence Rates ◽  
People With Dementia

SummaryAnxiety has reported prevalence rates between 38 and 72% among people with dementia. It has a negative impact on cognitive impairment and is associated with agitation and poor quality of life. The presence of excessive anxiety can be difficult to establish in people with dementia, especially when expressive or receptive speech is impaired. Unfortunately, there is a lack of research on the treatment of anxiety in dementia, and also on the wider issue of the management of anxiety disorders in old age. We explore the prevalence, presentation and diagnosis of anxiety in dementia and discuss the therapeutic options available.

scholarly journals Yeast volatiles double starvation survival in Drosophila

2021 ◽  
Vol 7 (20) ◽  
pp. eabf8896
Author(s):  
Yuan Luo ◽  
Jacob C. Johnson ◽  
Tuhin S. Chakraborty ◽  
Austin Piontkowski ◽  
Christi M. Gendron ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Transcription Factor ◽  
Signaling Pathways ◽  
Neural Circuits ◽  
Stress Signaling ◽  
Active Components ◽  
Dynamic Mechanisms ◽  
Starvation Survival ◽  
Live Yeast

Organisms make decisions based on the information they gather from their environment, the effects of which affect their fitness. Understanding how these interactions affect physiology may generate interventions that improve the length and quality of life. Here, we provide evidence that exposure to live yeast volatiles during starvation significantly extends survival, increases activity, and slows the rate of triacylglyceride (TAG) decline independent of canonical sensory perception. We demonstrate that ethanol (EtOH) is one of the active components in yeast volatiles that influences these phenotypes and that EtOH metabolites mediate dynamic mechanisms to promote Drosophila survival. Silencing R4d neurons reverses the ability of high EtOH concentrations to promote starvation survival, and their activation promotes EtOH metabolism. The transcription factor foxo promotes EtOH resistance, likely by protection from EtOH toxicity. Our results suggest that food-related cues recruit neural circuits and modulate stress signaling pathways to promote survival during starvation.

Sign in / Sign up

Export Citation Format

Share Document